End-of-day quote
Korea S.E.
18:00:00 2024-05-02 EDT
|
5-day change
|
1st Jan Change
|
4,140
KRW
|
+1.72%
|
|
+15.48%
|
-11.16%
|
03-08 |
QuantaMatrix Inc. announced that it has received KRW 17.5 billion in funding from Korea Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., The Korea Securities Finance Corporation, KB Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.
|
CI
| 03-07 |
QuantaMatrix Inc. announced that it expects to receive KRW 17.5 billion in funding from Korea Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., The Korea Securities Finance Corporation, KB Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.
|
CI
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
328,270
|
177,950
|
76,135
|
77,064
|
Enterprise Value (EV)
1 |
276,583
|
127,317
|
45,159
|
68,161
|
P/E ratio
|
-19.7
x
|
-8.97
x
|
-3.96
x
|
-3.57
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
194
x
|
324
x
|
59.2
x
|
24.7
x
|
EV / Revenue
|
164
x
|
232
x
|
35.1
x
|
21.9
x
|
EV / EBITDA
|
-21.2
x
|
-7.81
x
|
-2.56
x
|
-3.4
x
|
EV / FCF
|
-31.2
x
|
-9.7
x
|
-4.27
x
|
-4.72
x
|
FCF Yield
|
-3.2%
|
-10.3%
|
-23.4%
|
-21.2%
|
Price to Book
|
5.72
x
|
3.05
x
|
1.91
x
|
4.25
x
|
Nbr of stocks (in thousands)
|
14,655
|
16,477
|
16,479
|
16,537
|
Reference price
2 |
22,400
|
10,800
|
4,620
|
4,660
|
Announcement Date
|
21-03-23
|
22-03-23
|
23-03-23
|
24-03-21
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,689
|
549.8
|
1,286
|
3,118
|
EBITDA
1 |
-13,032
|
-16,296
|
-17,641
|
-20,054
|
EBIT
1 |
-14,831
|
-18,415
|
-20,018
|
-22,448
|
Operating Margin
|
-877.95%
|
-3,349.63%
|
-1,556.68%
|
-719.96%
|
Earnings before Tax (EBT)
1 |
-14,718
|
-18,180
|
-19,307
|
-21,630
|
Net income
1 |
-14,659
|
-18,116
|
-19,237
|
-21,556
|
Net margin
|
-867.72%
|
-3,295.13%
|
-1,495.97%
|
-691.35%
|
EPS
2 |
-1,139
|
-1,204
|
-1,167
|
-1,305
|
Free Cash Flow
1 |
-8,862
|
-13,132
|
-10,584
|
-14,437
|
FCF margin
|
-524.59%
|
-2,388.67%
|
-823.02%
|
-463.04%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-23
|
22-03-23
|
23-03-23
|
24-03-21
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
Net Cash position
1 |
51,687
|
50,632
|
30,976
|
8,903
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-8,862
|
-13,132
|
-10,584
|
-14,437
|
ROE (net income / shareholders' equity)
|
-33.8%
|
-31.3%
|
-39.2%
|
-74.3%
|
ROA (Net income/ Total Assets)
|
-19.6%
|
-18.4%
|
-22.9%
|
-41.1%
|
Assets
1 |
74,911
|
98,624
|
84,080
|
52,441
|
Book Value Per Share
2 |
3,917
|
3,544
|
2,420
|
1,096
|
Cash Flow per Share
2 |
647.0
|
547.0
|
123.0
|
415.0
|
Capex
1 |
1,108
|
2,763
|
485
|
861
|
Capex / Sales
|
65.6%
|
502.59%
|
37.69%
|
27.61%
|
Announcement Date
|
21-03-23
|
22-03-23
|
23-03-23
|
24-03-21
|
|
1st Jan change
|
Capi.
|
---|
| -11.16% | 49.12M | | -1.89% | 12.5B | | -9.59% | 7.67B | | +21.82% | 5.36B | | -1.31% | 5.26B | | +0.02% | 4.57B | | -50.89% | 3.15B | | +6.42% | 2.59B | | -10.02% | 2.06B | | -8.29% | 1.79B |
Diagnostic & Testing Substances
|